



KAREN L. SMITH, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

OFFICE OF AIDS
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2015-22

Date: December 2, 2015

TO: LOCAL ADAP COORDINATORS
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF
ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR
ALAFENAMIDE (GENVOYA®) TO THE ADAP FORMULARY

Effective December 2, 2015, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, (Genvoya®) has been added to the ADAP formulary.

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide is a fixed-dose antiretroviral (ARV) drug that was approved by the federal Food and Drug Administration on November 5, 2015 as a complete “one pill a day” single tablet regimen for the treatment of human immunodeficiency virus (HIV) 1 infection.

This ARV is a four-drug combination of elvitegravir 150 mg, an integrase strand transfer inhibitor; cobicistat 150 mg, a CYP3A inhibitor; and emtricitabine 200 mg and tenofovir alafenamide 10 mg, both HIV-1 nucleoside analog reverse transcriptase inhibitors. Three of the four single-ingredient drugs in this new combination drug are already on the ADAP formulary, elvitegravir (Vitekta), cobicistat (Tybost), and emtricitabine (Emtriva). The fourth drug, tenofovir alafenamide, is very similar to another drug currently on the ADAP formulary, tenofovir disoproxil fumarate (Viread). With the addition of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, ADAP has 195 drugs on the formulary.

Management Memorandum 2015-22

Page 2

December 2, 2015

If you have any questions regarding the addition of this ARV to the ADAP formulary, please contact me at (916) 449-5943 or Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.



Celia Banda-Brown, Chief
ADAP Section
Office of AIDS